Seeking Alpha

Human Genome (HGSI +0.6%) should still see a higher bid, says Baird, noting they "remain...

Human Genome (HGSI +0.6%) should still see a higher bid, says Baird, noting they "remain confident" that a higher bid will emerge despite Glaxo's (GSK +0.3%) indication it will suspend the tender offer while the company's poison pill is in effect. The firm met with management and said their calculations point to a bid closer to $20.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs